## CL: Colgate-Palmolive Company - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_20 -3.9% below STRENGTH zone (4.0-10.0%); PEG 1.60 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.31)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. RBC Capital upgrades Colgate-Palmolive stock to Outperform on favorable setup**
- Source: Investing.com UK | 20251209T090827 | Bullish | Relevance: 99%
- RBC Capital has upgraded Colgate-Palmolive Company (NYSE:CL) from Sector Perform to Outperform, maintaining an $88.00 price target. This decision comes despite recent stock pressure due to slowing global category growth, as RBC Capital believes current expectations are appropriately lowered and the risk-reward profile is favorable. The company recently reported increased net sales and EPS for Q2 2025, affirming its commitment to low single-digit EPS growth for the year.

**2. Natixis Sells 21,369 Shares of Colgate-Palmolive Company $CL**
- Source: MarketBeat | 20251209T123612 | Neutral | Relevance: 99%
- Natixis reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 12.5% in the second quarter, selling 21,369 shares and retaining 149,051 shares valued at $13.55 million. The stock currently holds a "Moderate Buy" consensus rating with an average target price of $89, despite recent price target reductions from several major analysts. Colgate-Palmolive pays a quarterly dividend of $0.52, resulting in an annualized yield of approximately 2.7%, and recently beat EPS estimates while slightly missing revenue expectations in its last quarterly report.

**3. Colgate-Palmolive Company (NYSE:CL) Declares $0.52 Quarterly Dividend**
- Source: MarketBeat | 20251211T155452 | Bullish | Relevance: 99%
-  Colgate-Palmolive Company (NYSE:CL) announced a quarterly dividend of $0.52 per share, payable on February 13th, with an ex-dividend date of January 21st. The company has increased its dividend for 63 consecutive years, boasts a payout ratio of approximately 53%, and analysts project its earnings will sufficiently cover future dividends. Shares traded up 0.8% to $78.39 after the company reported better-than-expected earnings of $0.91 EPS last quarter.

**4. Colgate-Palmolive (CL) Rated Outperform by RBC as Long-Term Growth Remains in Focus**
- Source: Insider Monkey | 20251211T023400 | Somewhat-Bullish | Relevance: 98%
- RBC Capital upgraded Colgate-Palmolive (NYSE:CL) to Outperform from Sector Perform, maintaining an $88 price target. Despite recent pressure from slower global category growth and a challenging 2026 outlook, RBC views the stock's setup as encouraging, anticipating a return to long-term growth goals. The company continues to demonstrate strong fundamentals, including healthy brands, market share, global presence, and a consistent dividend record.

**5. Argus downgrades Colgate-Palmolive stock rating to Hold from Buy**
- Source: Investing.com | 20251211T141211 | Neutral | Relevance: 98%
- Argus has downgraded Colgate-Palmolive (NYSE:CL) from Buy to Hold due to margin pressures and minimal growth prospects, despite the company's strong brand and dividend history. The consumer products giant is facing challenges from rising raw material costs and consumer uncertainty, leading to analysts revising earnings downwards and the stock trading near its 52-week low. However, RBC Capital recently upgraded Colgate-Palmolive to Outperform, citing renewed optimism after a period of sales growth slowdown.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Argus Research | $0 | $0 | 0% |
| 2025-12-09 | RBC Capital | $88 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Argus Research | down | Hold |
| 2025-12-09 | RBC Capital | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.07M) |
| Sells | 15 ($1.13M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.8% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.2%)
- Blackrock Inc.: 8.6% (+0.5%)
- State Street Corpora: 6.0% (+0.2%)
- Price (T.Rowe) Assoc: 4.0% (-11.5%)
- Geode Capital Manage: 2.7% (+4.1%)

### Key Risks

1. Long-term trend broken: trading 10.3% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.60 elevated, pricing in significant growth expectations. Forward P/E 20.1x stretched relative to 5% growth. Quality metrics strong (ROE 294%, ROA 15%). Balance sheet: $1.1B free cash flow. Insider selling cluster ($1.1M in 90 days), potential headwind. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $62.4B |
| Beta | 0.29 |
| 52W Range | $74.55 - $100.18 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.60 |
| Forward P/E | 20.1 |
| Current P/E | 21.1 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -3.9% (minimal 5-day change). Below STRENGTH zone by 7.9pp (needs >4.0% for momentum thesis). Below SMA200 (0.90x), long-term trend not supportive. RSI neutral at 45.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.94% (CS: 16) | Weak |
| RSI_14 | 44.9 | Neutral |
| MACD Histogram | -0.25 | Bearish |
| vs SMA20 | 0.982x | Below |
| vs SMA50 | 0.988x | Below |
| vs SMA200 | 0.897x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $77.25
- **Stop Loss:** $74.31 (3.8% risk)
- **Target:** $80.19 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 469
- **Position Value:** $36,230.25
- **Portfolio %:** 36.23%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-30 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.89 | $0.91 | +2.4% |
| 2025Q2 | $0.89 | $0.92 | +2.8% |
| 2025Q1 | $0.86 | $0.91 | +6.1% |
| 2024Q4 | $0.89 | $0.91 | +2.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*